Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1425-1431

  Rose, Markus A ^a   Schubert, R ^a   Kujumdshiev, S ^a   Kitz, R ^a   Zielen, S ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Immunogenicity; Pneumococcal; Preschool asthma; Vaccination

Indexed keywords

BACTERIUM ANTIBODY; BRONCHODILATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONTELUKAST; PNEUMOCOCCUS VACCINE;

ANTIBODY DETECTION; ARTICLE; ASTHMA; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTECTION; SEROTYPE; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTIBODIES, BACTERIAL; ASTHMA; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749871824     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01093.x     Document Type: Article

References (34)

1. WHO. Pneumococcal vaccines. WHO position paper. Weekly Epidemiol Rec 1999; 74: 177-83.
2. Black S, Shinefield H, Fireman B et.al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Paediatr Infect Dis J 2000; 19: 187-95.
3. Whitney CG, Farley MM, Hadler J et.al. Active bacterial core surveillance of the emerging infections program network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46.
4. Haby MM, Peat JK, Marks GB et.al. Asthma in preschool children: prevalence and risk factors. Thorax 2001; 56: 589-95.
5. Talbot TR, Hartert TV, Mitchel E et.al. Asthma is a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082-90.
6. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA and Orenstein WA, eds. Vaccines, 3rd edn. Philadelphia: W.B. Saunders Co., 1999: 553-607.
7. Rose M, Hey C, Kujumdshiev S et.al. Immunogenicity of pneumococcal vaccination of patients with cochlear implants. J Infect Dis 2004; 190: 551-7.
8. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Bethesda: National Institute of Health, NIH publication No. 02-3659, 2002.
9. STIKO (National Board for Immunization). Recommendations for the immunization of individuals at risk for pneumococcal infections. Epidemiol Bull 2004; 30: 242-3.
10. EMEA. Commission Decision Amending the Marketing Authorization for the Medicinal Product for Human Use "Prevenar - Pneumococcal Saccharide Conjugated Vaccine, Adsorbed", Var 18 type II, EU/1/00/167/001-007, (EMEA/H/C/323/II/18), 08/2004. London: EMEA, 2004.
11. Zielen S, Bröker M, Strnad N et.al. Simple determination of polysaccharide specific antibodies by means of chemically modified ELISA-Plates. J Immunol Meth 1996; 193: 1-7.
12. Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8: 266-72.
13. Schauer U, Stemberg F, Rieger CHL. IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with The Binding Site reagents. Clin Chem 2003; 49: 1924-9.
14. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series, No. 927, 2005, Annex 2. http://www.who.int/biologicals/publications/trs/areas/vaccines/pneumo/ en/index.html
15. Sanders EAM, Rijkers GT, Kuis W et.al. Defective anti-pneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol 1993; 91: 110-19.
16. Bernatowska-Matuszkiewicz E, Pac M, Pum M et.al. IgG subclasses and antibody response to pneumococcal capsular polysaccharides in children with severe sinopulmonary infections and asthma. Immunol Invest 1991; 20: 173-85.
17. De.Moraes. Lui C, Oliveria LC, Diogo CL et.al. Immunglobulin G subclass concentrations and infections in children and adolescents with severe asthma. Pediatr Allergy Immunol 2002; 12: 195-202.
18. Umetsu DT, Ambrosino DM, Quinti I et.al. Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency. N Engl J Med 1985; 313: 1247-51.
19. Bjorkander J, Bengtsson U, Oxelius VA et.al. Symptoms in patients with lowered levels of IgG subclasses, with or without IgA deficiency, and effects of immunoglobulin prophylaxis. Monogr Allergy 1986; 20: 157-63.
20. Zielen S, Bühring I, Ewald F et al. Immunoglobulin subclasses and polysaccharid specific immuno-deficiency states in patients with recurrent respiratory infections. Paediatr Pulmonol 1997; S16: 146-7.
21. Veenhoven R, Rijkers G, Schilder A et al. Immunoglobulins in otitis-prone children. Pediatr Res 2004; 55: 159-62.
22. American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases, 26th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2003: 492-97.
23. Schuller N. Prophylaxis of otitis media in asthmatic children. Pediatr Infect Dis 1983; 2: 280-3.
24. Lee HJ, Kang JH, Henrichsen J et al. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection. Vaccine 1995; 13: 1533-8.
25. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10: 811-13.
26. Zielen S, Buhring I, Strnad N et al. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in non-responders to the 23-valent pneumococcal vaccine. Infect Immun 2000; 68: 1435-40.
27. O'Brien KL, Swift AJ, Winkelstein JA. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM 197 among infants with sickle cell disease. Pediatrics 2000; 106: 965-72.
28. Nachman S, Kim S, King J et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112: 66-73.
29. Schubert R, Reichenbach J, Rose M et al. Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J 2004; 23: 269-70.
30. Anttila M, Eskola J, Ahman H, et al. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998; 177: 1614-21.
31. Obaro SK, Adegbola RA, Banya WAS, Grennwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348: 271-272.
32. Mbelle N, Huebner RE, Wasas AD et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumovcoccal conjugate vaccine. J Infect Dis 1999; 180: 1171-76.
33. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 2003; 21: 1815-25.
34. Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294: 2043-51.